Moderna : Verdict dans quelques semaines
>Un RS orienté logiquement sur la COVID-19 - Nous organisions vendredi dernier un roadshow avec Stéphane Bancel, CEO de Moderna. Cette présentation a été l’opportunité de revenir notamment sur le développement actuel de son vaccin contre la COVID-19 actuellement en phase 3 mais aussi sur les opportunités qui en découlent. Suite à cette journée, nous réitérons notre recommandation Achat en amont des premiers résultats intermédiaires ainsi que notre OC de 86 $. §hp...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.